intracavitary brachytherapy cervical cancer
Blue Cross & Blue Shield of Mississippi does not control such third
2016ï¼. Talk with your doctor and family members or friends about deciding to join a study. Obstetrics and Gynaecology Cases - Reviews is an open access peer-reviewed journal of obstetrics, gynaecology, focused to publish cases and reviews in all aspects of reproductive health. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment, Has a known additional malignancy that is progressing or has required active treatment within the past 3 years, Has severe hypersensitivity to pembrolizumab and/or any of its excipients, Has an active autoimmune disease that has required systemic treatment in past 2 years, Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis, Has an active infection requiring systemic therapy, Has a known history of Human Immunodeficiency Virus (HIV) infection, Has a known history of Hepatitis B or known active Hepatitis C virus infection, Has a history or current evidence of any condition, therapy, lab abnormality, or other circumstance that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results, and in the judgment of the investigator or Sponsor, would make the participant inappropriate for entry into this study, Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study, Has had an allogenic tissue/solid organ transplant, Has evidence of metastatic disease per RECIST 1.1 including lymph nodes above the first lumbar vertebra (L1) cephalad body, in the inguinal region. Unequivocal progression of non-target lesions is also considered PD. Study record managers: refer to the Data Element Definitions if submitting registration or results information. Participants receive placebo for pembrolizumab IV on Day 1 of each 3-week cycle (Q3W) for 5 cycles followed by placebo IV on Day 1 of each 6-week cycle (Q6W) for an additional 15 cycles. Copyright © 2007-2021, Blue Cross & Blue Shield of Mississippi, A Mutual Insurance Company. Khon Kaen University ( Site 1132), Contact: Study Coordinator +66 43 348 888, Ramathibodi Hospital, Mahidol University ( Site 1131), Rajthevee, Krung Thep Maha Nakhon, Thailand, 10400, Maharaj Nakorn Chiang Mai Hospital ( Site 1133), Contact: Study Coordinator +6653936046, I.U. Study of the effects of dwell time deviation constraints on inverse planning simulated annealing optimized plans of intracavitary brachytherapy of cancer cervix Saurabh Roy, V Subramani, Kishore Singh, Arun Kumar Rathi, Arora Savita, Aggarwal Aditi Universitaria Policlinico S. Orsola-Malpighi ( Site 0541), Contact: Study Coordinator +393478014769, Contact: Study Coordinator +39 0832661162, Contact: Study Coordinator +39 0226438003, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0542), Contact: Study Coordinator +390223902637, Fondazione Giovanni Pascale Di Napoli ( Site 0544), Contact: Study Coordinator +390815903637, Policlinico Universitario Gemelli ( Site 0538), Contact: Study Coordinator +390630158545, A.O.U. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Cancer 2005ï¼103ï¼92-101 ï¼ã¬ãã«â
¢ï¼ãå§ã 24ï¼ The myBlue Member, Employer, Agent and Provider portals are currently unavailable. NCCN Clinical Practice Guidelines in Oncology The other items of the questionnaire are lymphedema, peripheral neuropathy, menopausal symptom, sexual worry, sexual activity, and sexual enjoyment. Would you like to continue? To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. Therefore, you
party websites and is not responsible for the content, advice, products or
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. U.S. Department of Health and Human Services. Medical imaging helps position the radiation sources. Find a Network Provider in your area. We apologize for any inconvenience. European Network for Gynaecological Oncological Trial Groups. You have selected a link to a website operated by a third party. OS is the time from randomization to death due to any cause. Unequivocal progression of non-target lesions is also considered PD. enter another website not operated by Blue Cross & Blue Shield of Mississippi. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. (Clinical Trial), Triple (Participant, Investigator, Outcomes Assessor), A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047), Experimental: chemoradiotherapy + pembrolizumab, Experimental: chemoradiotherapy + placebo for pembrolizumab, 18 Years and older (Adult, Older Adult), Hoag Memorial Hospital Presbyterian ( Site 0038), Newport Beach, California, United States, 92663, Contact: Study Coordinator 949-764-6586, Smilow Cancer Center at Yale-New Haven ( Site 0023), New Haven, Connecticut, United States, 06510, Contact: Study Coordinator 203-200-4176, University of Kentucky Markey Cancer Center ( Site 0015), Lexington, Kentucky, United States, 40536, Contact: Study Coordinator 859-323-3065, Our Lady of the Lake Regional Medical Center. services offered therein. The appearance of one or more new lesions is also considered PD. OS data will be cumulated to a certain cut-off date and the analysis will be performed via Kaplan-Meier approach to estimate the OS rate at Month 36 using the entire OS data up to the cut-off date. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. Per RECIST 1.1, or by histopathologic confirmation of disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. Cervical cancer is the leading indication segment of the market, with an average of 500,000 females getting diagnosed every year. OS is the time from randomization to death due to any cause. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=not at all to 4=very much). Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common ⦠The cut-off date is event-driven and estimated to be approximately 46 months. Global scores are converted to a score of 0 to 100, with a higher score indicating improved health status. The cut-off date is event-driven and estimated to be approximately 38 months. Given as a total radiotherapy dose of 80 Gy for volume-directed and 75 Gy for point-directed. The 24 items use a 4-point scale (1=not at all to 4=very much) and are classified into 3 multi-item scales, 11 items with symptom experience, 3 items with body image, and 4 items with sexual/ vaginal functioning. During this window we have temporarily removed the Registration feature. informational purposes only and by providing these links to third party
The EORTC QLQ-CX24 is a questionnaire that rates the symptoms common to women with cervical cancer and evaluates the impact of disease and/or treatments. Please try again later. Braquiterapia (da palavra grega brachys, que significa "curta distância"), também conhecida por radioterapia interna, radioterapia de fonte selada, curieterapia ou endocurieterapia, é uma forma de radioterapia em que se coloca uma fonte de radiação dentro de, ou junto à área que necessita de tratamento. The change from baseline in EORTC QLQ-CX24 score will be presented. CR data will be cumulated to a certain cut-off date and the analysis will be performed to estimate the CR rate at Week 12 using the entire CR data up to the cut-off date. The standard of care chemoradiotherapy regimen includes cisplatin 40 mg/m^2 IV once per week (QW) for 5 or 6 weeks plus external beam radiotherapy (EBRT) followed by brachytherapy with minimum total radiotherapy dose of 80 Gray Units (Gy) for volume-directed and 75 Gy for point-directed given with the total duration of radiation treatment not to exceed 50 days (with an extension to a maximum of 56 days for unforeseen delays). Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Programmed Cell Death Receptor 1 (PD-1, PD1), Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator [ Time Frame: Up to approximately 38 months ], Overall Survival (OS) [ Time Frame: Up to approximately 46 months ], Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 38 months ], Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Month 24 as Assessed by the Investigator [ Time Frame: Up to approximately 38 months ], Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) at Month 24 as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 38 months ], Overall Survival (OS) at Month 36 [ Time Frame: Up to approximately 46 months ], Complete Response (CR) Rate Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) at Week 12 as Assessed by the Investigator [ Time Frame: Up to approximately 38 months ], Complete Response (CR) Rate Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) at Week 12 as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 38 months ], Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator [ Time Frame: Up to approximately 46 months ], Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 46 months ], Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by the Investigator [ Time Frame: Up to approximately 38 months ], Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 38 months ], Overall Survival (OS) in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by the Investigator [ Time Frame: Up to approximately 46 months ], Overall Survival (OS) in Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Participants as Assessed by Blinded Independent Central Review (BICR) [ Time Frame: Up to approximately 46 months ], Progression-Free Survival (PFS) After Next-Line Treatment (PFS 2) Following Discontinuation of Study Treatment [ Time Frame: Up to approximately 46 months ], Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score [ Time Frame: Baseline and up to approximately 46 months ], Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score [ Time Frame: Baseline and up to approximately 46 months ], Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score [ Time Frame: Baseline and up to approximately 46 months ], Number of Participants Who Experience One or More Adverse Events (AEs) [ Time Frame: Up to approximately 46 months ], Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) [ Time Frame: Up to approximately 46 months ], Has high-risk locally advanced cervical cancer (LACC): The International Federation of Gynecology and Obstetrics (FIGO) 2014 Stage IB2-IIB (with node-positive disease) or FIGO 2014 Stages III-IVA, Has histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix, Has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer, including investigational agents, and is immunotherapy-naïve, Female participants must not be pregnant or breastfeeding, and agree to use highly effective contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab or placebo and 180 days following the end of chemoradiotherapy and agrees not to donate eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during this period, Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment, Has provided a tissue sample from a core or excisional biopsy of a tumor lesion, Has radiographically evaluable disease, either measurable or non-measurable per RECIST 1.1, as assessed by the local site investigator/radiology, Has adequate organ within 7 days prior to the start of study treatment, Has undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy, Has bilateral hydronephrosis, unless at least one side has been stented or resolved by positioning of nephrostomy or considered mild and not clinically significant in the opinion of the investigator, Has anatomy or tumor geometry or any other reason or contraindication that cannot be treated with intracavitary brachytherapy or a combination of intracavitary and interstitial brachytherapy, Has received a live vaccine within 30 days prior to the first dose of study treatment, Has received treatment with systemic immunostimulatory agents, colony stimulating factors, interferons, interleukins and vaccine combinations within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1, Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1), anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137), Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to randomization, Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization. PFS data will be cumulated to a certain cut-off date and the analysis will be performed via Kaplan-Meier approach to estimate the PFS rate at Month 24 using the entire PFS data up to the cut-off date. Therefore, you are about to leave the Blue Cross & Blue Shield of Mississippi website and enter another website not operated by Blue Cross & Blue Shield of Mississippi. The change from baseline in EORTC QLQ-C30 score will be presented. A higher score indicates a better quality of life. Acta Oncol 2008ï¼47ï¼434-41ï¼ã¬ãã«â
¢ï¼ 5ï¼ Cervical Cancer Guidelineï¼Version 1. ( Site 0031), Baton Rouge, Louisiana, United States, 70817, Contact: Study Coordinator 225-214-6711, Covington, Louisiana, United States, 70433, Contact: Study Coordinator 985-892-2252, Contact: Study Coordinator 313-576-9435, University of New Mexico Comprehensive Care Center ( Site 0019), Albuquerque, New Mexico, United States, 87131, Contact: Study Coordinator 505-272-4946, University of North Carolina at Chapel Hill ( Site 0025), Chapel Hill, North Carolina, United States, 27514, Contact: Study Coordinator 919-966-4432, Sanford Bismarck Medical Center ( Site 0046), Bismarck, North Dakota, United States, 58501, Contact: Study Coordinator 605-312-3343, Contact: Study Coordinator 614-366-9091, Willamette Valley Cancer Institute and Research Center ( Site 8000), Contact: Study Coordinator 281-788-1616, Legacy Good Samaritan Medical Center ( Site 0013), Contact: Study Coordinator 503-413-7202, Allegheny Health Network West Penn Hospital-Gynecologic Oncology ( Site 0030), Pittsburgh, Pennsylvania, United States, 15244, Contact: Study Coordinator 412-578-4517, Texas Oncology-Fort Worth Cancer Center ( Site 8001), Texas Oncology-San Antonio Medical Center ( Site 8002), Texas Oncology-The Woodlands ( Site 8003), The Woodlands, Texas, United States, 77380, Charlottesville, Virginia, United States, 22903, Contact: Study Coordinator 434-924-2745, Virginia Commonwealth University ( Site 0024), Contact: Study Coordinator 804-827-4991, Westmead, New South Wales, Australia, 2145, Contact: Study Coordinator +612 9881 8421, Royal Brisbane and Women s Hospital ( Site 0972), Contact: Study Coordinator +617 3646 7983, Monash Health-Monash Medical Centre ( Site 0970), Contact: Study Coordinator +613 9595 6666, Peter MacCallum Cancer Centre ( Site 0971), Contact: Study Coordinator +613 8559 5000, Medizinische Universitat Innsbruck ( Site 0566), Contact: Study Coordinator +435050422345, Allgemeines Krankenhaus der Stadt Wien ( Site 0567), Contact: Study Coordinator +4314040027300, Contact: Study Coordinator +3234434788, Contact: Study Coordinator +3253724479, Contact: Study Coordinator +3292246624, Hospital das Clinicas da UFMG ( Site 0172), Belo Horizonte, Minas Gerais, Brazil, 30130-100, Contact: Study Coordinator +553134099255, Liga Norte Riograndense Contra o Cancer ( Site 0170), Natal, Rio Grande Do Norte, Brazil, 59075-740, Contact: Study Coordinator +558440095595, Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto USP ( Site 0171), Ribeirao Preto, Sao Paulo, Brazil, 14048-900, Contact: Study Coordinator +551636022482, IBCC - Instituto Brasileiro de Controle do Cancer ( Site 0166), Contact: Study Coordinator 551134744249, Princess Margaret Cancer Centre ( Site 0102), Contact: Study Coordinator 41694645015072, Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0101), Contact: Study Coordinator 514-890-8000, McGill University Health Centre ( Site 0105), CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Contact: Study Coordinator 418-691-5065, Sociedad de Investigaciones Medicas Limitadas ( Site 0194), Contact: Study Coordinator +56974316500, Santiago, Region M. De Santiago, Chile, 7510032, Contact: Study Coordinator +56998634501, Santiago, Region M. De Santiago, Chile, 7630370, Contact: Study Coordinator +56931912746, Contact: Study Coordinator +56992369820, Contact: Study Coordinator +862122112894, Anhui Provincial Cancer Hospital ( Site 1007), Contact: Study Coordinator 13355515031, Peking Union Medical College Hospital ( Site 1001), Contact: Study Coordinator +8613511050222, Contact: Study Coordinator +8613708384529, The First Affiliated Hospital of Xiamen University ( Site 1025), Contact: Study Coordinator +865922137572, Harbin Medical University Cancer Hospital ( Site 1013), Contact: Study Coordinator +8613604843878, Xiangya Hospital Central-South University ( Site 1009), Contact: Study Coordinator 0731-84327458, Contact: Study Coordinator +862164175590, Contact: Study Coordinator +8618908178800, Zhejiang Provincial People's Hospital ( Site 1021), Contact: Study Coordinator 18868423773, Contact: Study Coordinator 15988109696, Fundacion Centro de Investigacion Clinica CIC ( Site 0231), Contact: Study Coordinator +573004949197, Instituto Nacional de Cancerologia E.S.E ( Site 0228), Bogota, Distrito Capital De Bogota, Colombia, 110321, Contact: Study Coordinator +573182099417, Centro Medico Imbanaco de Cali S.A ( Site 0227), Contact: Study Coordinator +573155028668, Contact: Study Coordinator +420532233843, Ostrava, Moravskoslezsky Kraj, Czechia, 708 52, Contact: Study Coordinator +420597371111, Fakultni nemocnice Kralovske Vinohrady ( Site 0913), Contact: Study Coordinator +420267163195, Contact: Study Coordinator 33531155101, Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0321), Contact: Study Coordinator +50242142081, Contact: Study Coordinator +50254530410, Contact: Study Coordinator +50256973689, Contact: Study Coordinator +50240492110, Contact: Study Coordinator +50222505555, Centro Medico Integral De Cancerología (CEMIC) ( Site 0322), Contact: Study Coordinator +50231512277, Contact: Study Coordinator +3612248600/3317, Debreceni Egyetem Klinikai Kozpont ( Site 0845), Contact: Study Coordinator +3630 747 7654, Contact: Study Coordinator 97236974516, Contact: Study Coordinator +97247773872, Hadassah Medical Center. Links to third party websites are provided for
for cervical cancer using high dose rate intracavitary brachytherapyï¼study of JROSGï¼Japan Radiation Oncology Study Groupï¼. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. websites or the content, advice, products or services offered therein. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. We apologize for any inconvenience. The EORTC QLQ-C30 is a questionnaire that rates the overall quality of life in cancer participants. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04221945. Long-term results of high dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Has anatomy or tumor geometry or any other reason or contraindication that cannot be treated with intracavitary brachytherapy or a combination of intracavitary and interstitial brachytherapy; Has received a live vaccine within 30 days prior to the first dose of study treatment é£éç¾æ£ç¨èªè§£èª¬éãé£éç診æã»æ²»çã¬ã¤ãã©ã¤ã³ | the japan esophageal society.ï½æ¥æ¬é£éå¦ä¼äºåå± ã130-0012 æ±äº¬é½å¢¨ç°åºå¤ªå¹³2-3-13 廣ç¬ãã«ãã£ã³ã°4é tel/fax: 03-6456-1339 Brachytherapy is an international and multidisciplinary journal that publishes original peer-reviewed articles and selected reviews on the techniques and clinical applications of interstitial radiation, endovascular brachytherapy, and systemic brachytherapy in the management of cancer and cardiac and other diseases. For participants who demonstrated a confirmed Complete Response (CR: Disappearance of all target and non-target lesions and also includes reduction of all nodal lesions to <10mm) per RECIST 1.1, CR rate is defined as the percentage of participants who experienced a CR. The cut-off date is estimated to be approximately 38 months. Choosing to participate in a study is an important personal decision. Per RECIST 1.1, or by histopathologic confirmation of disease progression, PD is defined as ≥20% increase in the sum of diameters of target lesions. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Please remove one or more studies before adding more. Cerrahpasa Medical Faculty ( Site 0755), Contact: Study Coordinator +905422156474, Contact: Study Coordinator +905337660201, Baskent Universitesi Ankara Hastanesi ( Site 0754), Contact: Study Coordinator +905325798687, Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 0876), Kharkiv, Kharkivska Oblast, Ukraine, 61024, Contact: Study Coordinator +380958816458. The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. You have reached the maximum number of saved studies (100). All Rights Reserved. Citta della Salute e della Scienza di Torino ( Site 0535), Contact: Study Coordinator +390113131523, Aichi Cancer Center Hospital ( Site 1155), Contact: Study Coordinator +81527626111, National Hospital Organization Shikoku Cancer Center ( Site 1162), Contact: Study Coordinator +81899991111, Contact: Study Coordinator +81899645111, Contact: Study Coordinator +81-942-35-3311, Hokkaido University Hospital ( Site 1163), Contact: Study Coordinator +81-11-716-1161, Iwate Medical University Hospital ( Site 1165), Contact: Study Coordinator +81-19-613-7111, University of the Ryukyus Hospital ( Site 1156), Contact: Study Coordinator +81988953331, Saitama Medical University International Medical Center ( Site 1168), Contact: Study Coordinator +81-42-984-4111, Contact: Study Coordinator +81-48-722-1111, Contact: Study Coordinator +81422475511, National Hospital Organization Kyushu Cancer Center ( Site 1167), Contact: Study Coordinator +81-92-541-3231, Contact: Study Coordinator +81-99-230-7000, Osaka International Cancer Institute ( Site 1161), Contact: Study Coordinator +81669451181, Contact: Study Coordinator +81-3-3353-1211, Goyang-si, Kyonggi-do, Korea, Republic of, 10408, Contact: Study Coordinator +82-31-920-1760, Contact: Study Coordinator +82230107178, Keimyung University Dongsan Medical Center ( Site 1066), Daegu, Taegu-Kwangyokshi, Korea, Republic of, 42601, Contact: Study Coordinator +82532507518, Contact: Study Coordinator +82222282246, Contact: Study Coordinator +82-2-3410-3513, Helse Bergen HF Haukeland Universitetssjukehus ( Site 0601), Contact: Study Coordinator +47 55974200, Oslo Universitetssykehus Radiumhospitalet ( Site 0600), Contact: Study Coordinator +47 22934000, Contact: Study Coordinator +51959947601, Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 0287), Contact: Study Coordinator +51964820298, Hospital Nacional Daniel Alcides Carrion ( Site 0293), Contact: Study Coordinator +511997889111, Contact: Study Coordinator 51945334003, Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 0290), Contact: Study Coordinator 51995220364, Hospital Nacional Arzobispo Loayza ( Site 0292), Contact: Study Coordinator +51950273809, Hospital Nacional Guillermo Almenara Irigoyen ( Site 0291), Contact: Study Coordinator +51999903343, Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 0741), Chelyabinsk, Chelyabinskaya Oblast, Russian Federation, 454087, Contact: Study Coordinator +79517763791, Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0729), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation, 660133, Contact: Study Coordinator +89131893995, MSROI named after P.A. Articles are peer reviewed by clinicians or researchers expert in the field of Obstetrics and Gynaecology. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. ClinicalTrials.gov Identifier: NCT04221945, Interventional
are about to leave the Blue Cross & Blue Shield of Mississippi website and